Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 349 to 355 of 355 entries
Sorted by: Best Match Show Resources per page
Cardiac late effects after modern 3D-conformal radiotherapy in breast cancer patients: a retrospective cohort study in Germany (ESCaRa).

Breast cancer research and treatment

Merzenich H, Baaken D, Schmidt M, Bekes I, Schwentner L, Janni W, Woeckel A, Bartkowiak D, Wiegel T, Blettner M, Wollschläger D, Schmidberger H.
PMID: 34626275
Breast Cancer Res Treat. 2022 Jan;191(1):147-157. doi: 10.1007/s10549-021-06412-3. Epub 2021 Oct 09.

PURPOSE: Radiotherapy (RT) was identified as a risk factor for long-term cardiac effects in breast cancer patients treated until the 1990s. However, modern techniques reduce radiation exposure of the heart, but some exposure remains unavoidable. In a retrospective cohort...

Cite
Merzenich H, Baaken D, Schmidt M, et al. Cardiac late effects after modern 3D-conformal radiotherapy in breast cancer patients: a retrospective cohort study in Germany (ESCaRa). Breast Cancer Res Treat. 2021;191(1):147-157doi: 10.1007/s10549-021-06412-3.
Merzenich, H., Baaken, D., Schmidt, M., Bekes, I., Schwentner, L., Janni, W., Woeckel, A., Bartkowiak, D., Wiegel, T., Blettner, M., Wollschläger, D., & Schmidberger, H. (2022). Cardiac late effects after modern 3D-conformal radiotherapy in breast cancer patients: a retrospective cohort study in Germany (ESCaRa). Breast cancer research and treatment, 191(1), 147-157. https://doi.org/10.1007/s10549-021-06412-3
Merzenich, Hiltrud, et al. "Cardiac late effects after modern 3D-conformal radiotherapy in breast cancer patients: a retrospective cohort study in Germany (ESCaRa)." Breast cancer research and treatment vol. 191,1 (2022): 147-157. doi: https://doi.org/10.1007/s10549-021-06412-3
Merzenich H, Baaken D, Schmidt M, Bekes I, Schwentner L, Janni W, Woeckel A, Bartkowiak D, Wiegel T, Blettner M, Wollschläger D, Schmidberger H. Cardiac late effects after modern 3D-conformal radiotherapy in breast cancer patients: a retrospective cohort study in Germany (ESCaRa). Breast Cancer Res Treat. 2022 Jan;191(1):147-157. doi: 10.1007/s10549-021-06412-3. Epub 2021 Oct 09. PMID: 34626275.
Copy Download .nbib Format: NLM
Efficacy and Safety of COVID-19 Convalescent Plasma in Hospitalized Patients: A Randomized Clinical Trial.

JAMA internal medicine

Ortigoza MB, Yoon H, Goldfeld KS, Troxel AB, Daily JP, Wu Y, Li Y, Wu D, Cobb GF, Baptiste G, O'Keeffe M, Corpuz MO, Ostrosky-Zeichner L, Amin A, Zacharioudakis IM, Jayaweera DT, Wu Y, Philley JV, Devine MS, Desruisseaux MS, Santin AD, Anjan S, Mathew R, Patel B, Nigo M, Upadhyay R, Kupferman T, Dentino AN, Nanchal R, Merlo CA, Hager DN, Chandran K, Lai JR, Rivera J, Bikash CR, Lasso G, Hilbert TP, Paroder M, Asencio AA, Liu M, Petkova E, Bragat A, Shaker R, McPherson DD, Sacco RL, Keller MJ, Grudzen CR, Hochman JS, Pirofski LA, Parameswaran L, Corcoran AT, Rohatgi A, Wronska MW, Wu X, Srinivasan R, Deng FM, Filardo TD, Pendse J, Blaser SB, Whyte O, Gallagher JM, Thomas OE, Ramos D, Sturm-Reganato CL, Fong CC, Daus IM, Payoen AG, Chiofolo JT, Friedman MT, Wu DW, Jacobson JL, Schneider JG, Sarwar UN, Wang HE, Huebinger RM, Dronavalli G, Bai Y, Grimes CZ, Eldin KW, Umana VE, Martin JG, Heath TR, Bello FO, Ransford DL, Laurent-Rolle M, Shenoi SV, Akide-Ndunge OB, Thapa B, Peterson JL, Knauf K, Patel SU, Cheney LL, Tormey CA, Hendrickson JE.
PMID: 34901997
JAMA Intern Med. 2021 Dec 13; doi: 10.1001/jamainternmed.2021.6850. Epub 2021 Dec 13.

IMPORTANCE: There is clinical equipoise for COVID-19 convalescent plasma (CCP) use in patients hospitalized with COVID-19.OBJECTIVE: To determine the safety and efficacy of CCP compared with placebo in hospitalized patients with COVID-19 receiving noninvasive supplemental oxygen.DESIGN, SETTING, AND PARTICIPANTS:...

Cite
Ortigoza MB, Yoon H, Goldfeld KS, et al. Efficacy and Safety of COVID-19 Convalescent Plasma in Hospitalized Patients: A Randomized Clinical Trial. JAMA Intern Med. 2021;doi: 10.1001/jamainternmed.2021.6850.
Ortigoza, M. B., Yoon, H., Goldfeld, K. S., Troxel, A. B., Daily, J. P., Wu, Y., Li, Y., Wu, D., Cobb, G. F., Baptiste, G., O'Keeffe, M., Corpuz, M. O., Ostrosky-Zeichner, L., Amin, A., Zacharioudakis, I. M., Jayaweera, D. T., Wu, Y., Philley, J. V., Devine, M. S., Desruisseaux, M. S., Santin, A. D., Anjan, S., Mathew, R., Patel, B., Nigo, M., Upadhyay, R., Kupferman, T., Dentino, A. N., Nanchal, R., Merlo, C. A., Hager, D. N., Chandran, K., Lai, J. R., Rivera, J., Bikash, C. R., Lasso, G., Hilbert, T. P., Paroder, M., Asencio, A. A., Liu, M., Petkova, E., Bragat, A., Shaker, R., McPherson, D. D., Sacco, R. L., Keller, M. J., Grudzen, C. R., Hochman, J. S., Pirofski, L. A., Parameswaran, L., Corcoran, A. T., Rohatgi, A., Wronska, M. W., Wu, X., Srinivasan, R., Deng, F. M., Filardo, T. D., Pendse, J., Blaser, S. B., Whyte, O., Gallagher, J. M., Thomas, O. E., Ramos, D., Sturm-Reganato, C. L., Fong, C. C., Daus, I. M., Payoen, A. G., Chiofolo, J. T., Friedman, M. T., Wu, D. W., Jacobson, J. L., Schneider, J. G., Sarwar, U. N., Wang, H. E., Huebinger, R. M., Dronavalli, G., Bai, Y., Grimes, C. Z., Eldin, K. W., Umana, V. E., Martin, J. G., Heath, T. R., Bello, F. O., Ransford, D. L., Laurent-Rolle, M., Shenoi, S. V., Akide-Ndunge, O. B., Thapa, B., Peterson, J. L., Knauf, K., Patel, S. U., Cheney, L. L., Tormey, C. A., & Hendrickson, J. E. (2021). Efficacy and Safety of COVID-19 Convalescent Plasma in Hospitalized Patients: A Randomized Clinical Trial. JAMA internal medicine, . https://doi.org/10.1001/jamainternmed.2021.6850
Ortigoza, Mila B, et al. "Efficacy and Safety of COVID-19 Convalescent Plasma in Hospitalized Patients: A Randomized Clinical Trial." JAMA internal medicine vol. (2021). doi: https://doi.org/10.1001/jamainternmed.2021.6850
Ortigoza MB, Yoon H, Goldfeld KS, Troxel AB, Daily JP, Wu Y, Li Y, Wu D, Cobb GF, Baptiste G, O'Keeffe M, Corpuz MO, Ostrosky-Zeichner L, Amin A, Zacharioudakis IM, Jayaweera DT, Wu Y, Philley JV, Devine MS, Desruisseaux MS, Santin AD, Anjan S, Mathew R, Patel B, Nigo M, Upadhyay R, Kupferman T, Dentino AN, Nanchal R, Merlo CA, Hager DN, Chandran K, Lai JR, Rivera J, Bikash CR, Lasso G, Hilbert TP, Paroder M, Asencio AA, Liu M, Petkova E, Bragat A, Shaker R, McPherson DD, Sacco RL, Keller MJ, Grudzen CR, Hochman JS, Pirofski LA, Parameswaran L, Corcoran AT, Rohatgi A, Wronska MW, Wu X, Srinivasan R, Deng FM, Filardo TD, Pendse J, Blaser SB, Whyte O, Gallagher JM, Thomas OE, Ramos D, Sturm-Reganato CL, Fong CC, Daus IM, Payoen AG, Chiofolo JT, Friedman MT, Wu DW, Jacobson JL, Schneider JG, Sarwar UN, Wang HE, Huebinger RM, Dronavalli G, Bai Y, Grimes CZ, Eldin KW, Umana VE, Martin JG, Heath TR, Bello FO, Ransford DL, Laurent-Rolle M, Shenoi SV, Akide-Ndunge OB, Thapa B, Peterson JL, Knauf K, Patel SU, Cheney LL, Tormey CA, Hendrickson JE. Efficacy and Safety of COVID-19 Convalescent Plasma in Hospitalized Patients: A Randomized Clinical Trial. JAMA Intern Med. 2021 Dec 13; doi: 10.1001/jamainternmed.2021.6850. Epub 2021 Dec 13. PMID: 34901997.
Copy Download .nbib Format: NLM
Update Breast Cancer 2020 Part 5 - Moving Therapies From Advanced to Early Breast Cancer Patients.

Geburtshilfe und Frauenheilkunde

Lux MP, Schneeweiss A, Hartkopf AD, Müller V, Janni W, Belleville E, Stickeler E, Thill M, Fasching PA, Kolberg HC, Untch M, Harbeck N, Wöckel A, Thomssen C, Schulmeyer CE, Welslau M, Overkamp F, Schütz F, Lüftner D, Ditsch N.
PMID: 33867564
Geburtshilfe Frauenheilkd. 2021 Apr;81(4):469-480. doi: 10.1055/a-1397-7170. Epub 2021 Apr 14.

In recent years, significant progress has been made in new therapeutic approaches to breast cancer, particularly in patients with HER2-positive and HER2-negative/hormone receptor-positive (HR+) breast cancer. In the case of HER2-positive tumours, these approaches have included, in particular, treatment...

Cite
Lux MP, Schneeweiss A, Hartkopf AD, et al. Update Breast Cancer 2020 Part 5 - Moving Therapies From Advanced to Early Breast Cancer Patients. Geburtshilfe Frauenheilkd. 2021;81(4):469-480doi: 10.1055/a-1397-7170.
Lux, M. P., Schneeweiss, A., Hartkopf, A. D., Müller, V., Janni, W., Belleville, E., Stickeler, E., Thill, M., Fasching, P. A., Kolberg, H. C., Untch, M., Harbeck, N., Wöckel, A., Thomssen, C., Schulmeyer, C. E., Welslau, M., Overkamp, F., Schütz, F., Lüftner, D., & Ditsch, N. (2021). Update Breast Cancer 2020 Part 5 - Moving Therapies From Advanced to Early Breast Cancer Patients. Geburtshilfe und Frauenheilkunde, 81(4), 469-480. https://doi.org/10.1055/a-1397-7170
Lux, Michael P, et al. "Update Breast Cancer 2020 Part 5 - Moving Therapies From Advanced to Early Breast Cancer Patients." Geburtshilfe und Frauenheilkunde vol. 81,4 (2021): 469-480. doi: https://doi.org/10.1055/a-1397-7170
Lux MP, Schneeweiss A, Hartkopf AD, Müller V, Janni W, Belleville E, Stickeler E, Thill M, Fasching PA, Kolberg HC, Untch M, Harbeck N, Wöckel A, Thomssen C, Schulmeyer CE, Welslau M, Overkamp F, Schütz F, Lüftner D, Ditsch N. Update Breast Cancer 2020 Part 5 - Moving Therapies From Advanced to Early Breast Cancer Patients. Geburtshilfe Frauenheilkd. 2021 Apr;81(4):469-480. doi: 10.1055/a-1397-7170. Epub 2021 Apr 14. PMID: 33867564; PMCID: PMC8046519.
Copy Download .nbib Format: NLM
Age-related activity of Poly (ADP-Ribose) Polymerase (PARP) in men with localized prostate cancer.

Mechanisms of ageing and development

Deniz M, Zengerling F, Gundelach T, Moreno-Villanueva M, Bürkle A, Janni W, Bolenz C, Kostezka S, Marienfeld R, Benckendorff J, Friedl TWP, Wiesmüller L, Rall-Scharpf M.
PMID: 33887280
Mech Ageing Dev. 2021 Jun;196:111494. doi: 10.1016/j.mad.2021.111494. Epub 2021 Apr 19.

Mutations in DNA repair genes have been connected with familial prostate cancer and sensitivity to targeted drugs like PARP-inhibitors. Clinical use of this information is limited by the small fraction of prostate cancer risk gene carriers, variants of unknown...

Cite
Deniz M, Zengerling F, Gundelach T, et al. Age-related activity of Poly (ADP-Ribose) Polymerase (PARP) in men with localized prostate cancer. Mech Ageing Dev. 2021;196:111494doi: 10.1016/j.mad.2021.111494.
Deniz, M., Zengerling, F., Gundelach, T., Moreno-Villanueva, M., Bürkle, A., Janni, W., Bolenz, C., Kostezka, S., Marienfeld, R., Benckendorff, J., Friedl, T. W. P., Wiesmüller, L., & Rall-Scharpf, M. (2021). Age-related activity of Poly (ADP-Ribose) Polymerase (PARP) in men with localized prostate cancer. Mechanisms of ageing and development, 196111494. https://doi.org/10.1016/j.mad.2021.111494
Deniz, Miriam, et al. "Age-related activity of Poly (ADP-Ribose) Polymerase (PARP) in men with localized prostate cancer." Mechanisms of ageing and development vol. 196 (2021): 111494. doi: https://doi.org/10.1016/j.mad.2021.111494
Deniz M, Zengerling F, Gundelach T, Moreno-Villanueva M, Bürkle A, Janni W, Bolenz C, Kostezka S, Marienfeld R, Benckendorff J, Friedl TWP, Wiesmüller L, Rall-Scharpf M. Age-related activity of Poly (ADP-Ribose) Polymerase (PARP) in men with localized prostate cancer. Mech Ageing Dev. 2021 Jun;196:111494. doi: 10.1016/j.mad.2021.111494. Epub 2021 Apr 19. PMID: 33887280.
Copy Download .nbib Format: NLM
Prognostic relevance of the HER2 status of circulating tumor cells in metastatic breast cancer patients screened for participation in the DETECT study program.

ESMO open

Müller V, Banys-Paluchowski M, Friedl TWP, Fasching PA, Schneeweiss A, Hartkopf A, Wallwiener D, Rack B, Meier-Stiegen F, Huober J, Rübner M, Hoffmann O, Müller L, Janni W, Wimberger P, Jäger B, Pantel K, Riethdorf S, Harbeck N, Fehm T.
PMID: 34839105
ESMO Open. 2021 Dec;6(6):100299. doi: 10.1016/j.esmoop.2021.100299. Epub 2021 Nov 25.

BACKGROUND: Circulating tumor cells (CTCs) have been reported to predict clinical outcome in metastatic breast cancer (MBC). Biology of CTCs may differ from that of the primary tumor and HER2-positive CTCs are found in some patients with HER2-negative tumors.PATIENTS...

Cite
Müller V, Banys-Paluchowski M, Friedl TWP, et al. Prognostic relevance of the HER2 status of circulating tumor cells in metastatic breast cancer patients screened for participation in the DETECT study program. ESMO Open. 2021;6(6):100299doi: 10.1016/j.esmoop.2021.100299.
Müller, V., Banys-Paluchowski, M., Friedl, T. W. P., Fasching, P. A., Schneeweiss, A., Hartkopf, A., Wallwiener, D., Rack, B., Meier-Stiegen, F., Huober, J., Rübner, M., Hoffmann, O., Müller, L., Janni, W., Wimberger, P., Jäger, B., Pantel, K., Riethdorf, S., Harbeck, N., Fehm, T. (2021). Prognostic relevance of the HER2 status of circulating tumor cells in metastatic breast cancer patients screened for participation in the DETECT study program. ESMO open, 6(6), 100299. https://doi.org/10.1016/j.esmoop.2021.100299
Müller, V, et al. "Prognostic relevance of the HER2 status of circulating tumor cells in metastatic breast cancer patients screened for participation in the DETECT study program." ESMO open vol. 6,6 (2021): 100299. doi: https://doi.org/10.1016/j.esmoop.2021.100299
Müller V, Banys-Paluchowski M, Friedl TWP, Fasching PA, Schneeweiss A, Hartkopf A, Wallwiener D, Rack B, Meier-Stiegen F, Huober J, Rübner M, Hoffmann O, Müller L, Janni W, Wimberger P, Jäger B, Pantel K, Riethdorf S, Harbeck N, Fehm T. Prognostic relevance of the HER2 status of circulating tumor cells in metastatic breast cancer patients screened for participation in the DETECT study program. ESMO Open. 2021 Dec;6(6):100299. doi: 10.1016/j.esmoop.2021.100299. Epub 2021 Nov 25. PMID: 34839105; PMCID: PMC8637493.
Copy Download .nbib Format: NLM
Prognostic relevance of the HER2 status of circulating tumor cells in metastatic breast cancer patients screened for participation in the DETECT study program.

ESMO open

Müller V, Banys-Paluchowski M, Friedl TWP, Fasching PA, Schneeweiss A, Hartkopf A, Wallwiener D, Rack B, Meier-Stiegen F, Huober J, Rübner M, Hoffmann O, Müller L, Janni W, Wimberger P, Jäger B, Pantel K, Riethdorf S, Harbeck N, Fehm T.
PMID: 34839105
ESMO Open. 2021 Nov 25;6(6):100299. doi: 10.1016/j.esmoop.2021.100299. Epub 2021 Nov 25.

BACKGROUND: Circulating tumor cells (CTCs) have been reported to predict clinical outcome in metastatic breast cancer (MBC). Biology of CTCs may differ from that of the primary tumor and HER2-positive CTCs are found in some patients with HER2-negative tumors.PATIENTS...

Cite
Müller V, Banys-Paluchowski M, Friedl TWP, et al. Prognostic relevance of the HER2 status of circulating tumor cells in metastatic breast cancer patients screened for participation in the DETECT study program. ESMO Open. 2021;6(6):100299doi: 10.1016/j.esmoop.2021.100299.
Müller, V., Banys-Paluchowski, M., Friedl, T. W. P., Fasching, P. A., Schneeweiss, A., Hartkopf, A., Wallwiener, D., Rack, B., Meier-Stiegen, F., Huober, J., Rübner, M., Hoffmann, O., Müller, L., Janni, W., Wimberger, P., Jäger, B., Pantel, K., Riethdorf, S., Harbeck, N., Fehm, T. (2021). Prognostic relevance of the HER2 status of circulating tumor cells in metastatic breast cancer patients screened for participation in the DETECT study program. ESMO open, 6(6), 100299. https://doi.org/10.1016/j.esmoop.2021.100299
Müller, V, et al. "Prognostic relevance of the HER2 status of circulating tumor cells in metastatic breast cancer patients screened for participation in the DETECT study program." ESMO open vol. 6,6 (2021): 100299. doi: https://doi.org/10.1016/j.esmoop.2021.100299
Müller V, Banys-Paluchowski M, Friedl TWP, Fasching PA, Schneeweiss A, Hartkopf A, Wallwiener D, Rack B, Meier-Stiegen F, Huober J, Rübner M, Hoffmann O, Müller L, Janni W, Wimberger P, Jäger B, Pantel K, Riethdorf S, Harbeck N, Fehm T. Prognostic relevance of the HER2 status of circulating tumor cells in metastatic breast cancer patients screened for participation in the DETECT study program. ESMO Open. 2021 Nov 25;6(6):100299. doi: 10.1016/j.esmoop.2021.100299. Epub 2021 Nov 25. PMID: 34839105; PMCID: PMC8637493.
Copy Download .nbib Format: NLM
Evidence of Adaptive Evolution in .

Viruses

Bhattacharya T, Rice DW, Crawford JM, Hardy RW, Newton ILG.
PMID: 34452330
Viruses. 2021 Jul 27;13(8). doi: 10.3390/v13081464.

Eukaryotic nucleic acid methyltransferase (MTase) proteins are essential mediators of epigenetic and epitranscriptomic regulation. DNMT2 belongs to a large, conserved family of DNA MTases found in many organisms, including holometabolous insects such as fruit flies and mosquitoes, where it...

Cite
Bhattacharya T, Rice DW, Crawford JM, et al. Evidence of Adaptive Evolution in . Viruses. 2021;13(8)doi: 10.3390/v13081464.
Bhattacharya, T., Rice, D. W., Crawford, J. M., Hardy, R. W., & Newton, I. L. G. (2021). Evidence of Adaptive Evolution in . Viruses, 13(8), . https://doi.org/10.3390/v13081464
Bhattacharya, Tamanash, et al. "Evidence of Adaptive Evolution in ." Viruses vol. 13,8 (2021). doi: https://doi.org/10.3390/v13081464
Bhattacharya T, Rice DW, Crawford JM, Hardy RW, Newton ILG. Evidence of Adaptive Evolution in . Viruses. 2021 Jul 27;13(8). doi: 10.3390/v13081464. PMID: 34452330; PMCID: PMC8402854.
Copy Download .nbib Format: NLM
Showing 349 to 355 of 355 entries